Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$563.00 USD

563.00
1,024,320

+3.20 (0.57%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $563.06 +0.06 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alnylam Reports Positive Data on Lumasiran in Renal Disease

by Zacks Equity Research

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.

    Zacks Equity Research

    Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

    by Zacks Equity Research

    The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

      Zacks Equity Research

      Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta

      by Zacks Equity Research

      Mylan (MYL) and partner Biocon get a significant boost with the FDA approval for Fulphila, a biosimilar of Amgen's Neulasta.

        Zacks Equity Research

        Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?

        by Zacks Equity Research

        Regeneron Pharmaceuticals (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          David Borun headshot

          Is Genome Editing the Next Biotech Breakthrough?

          by David Borun

          CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

            Zacks Equity Research

            Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

            by Zacks Equity Research

            Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

              Zacks Equity Research

              Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

              by Zacks Equity Research

              Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

                Zacks Equity Research

                Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

                by Zacks Equity Research

                Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

                  Ritujay Ghosh headshot

                  Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?

                  by Ritujay Ghosh

                  Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.

                    Zacks Equity Research

                    Inovio's (INO) Q1 Loss Wider than Expected, Shares Down

                    by Zacks Equity Research

                    Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.

                      Zacks Equity Research

                      Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus

                      by Zacks Equity Research

                      Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.

                        Zacks Equity Research

                        Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

                        by Zacks Equity Research

                        Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.

                          Ekta Bagri headshot

                          Regeneron (REGN) Beats on Q1 Earnings

                          by Ekta Bagri

                          Regeneron beat on earnings in the first quarter. However, sales fell short of expectations.

                            Zacks Equity Research

                            Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

                            by Zacks Equity Research

                            The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

                              Zacks Equity Research

                              Is a Beat in Store for Adverum (ADVM) This Earnings Season?

                              by Zacks Equity Research

                              Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.

                                Zacks Equity Research

                                What's in the Offing for Regeneron (REGN) in Q1 Earnings?

                                by Zacks Equity Research

                                Investors are expected to focus on Eylea's performance and Dupixent's uptake when Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2018 results on May 3.

                                  Zacks Equity Research

                                  Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark

                                  by Zacks Equity Research

                                  Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.

                                    Zacks Equity Research

                                    Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y

                                    by Zacks Equity Research

                                    Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.

                                      Zacks Equity Research

                                      FDA Restricts Sale of Bayer's Essure Birth Control Device

                                      by Zacks Equity Research

                                      FDA puts restriction on the sale of Bayer's (BAYRY) implanted birth control device Essure.

                                        Zacks Equity Research

                                        FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

                                        by Zacks Equity Research

                                        Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

                                          Zacks Equity Research

                                          Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why

                                          by Zacks Equity Research

                                          Let us look at the factors that have led to the increase in share price of Emergent (EBS).

                                            Zacks Equity Research

                                            Novo Nordisk Obtains Licence for Sickle Cell Disease Program

                                            by Zacks Equity Research

                                            Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

                                              Zacks Equity Research

                                              Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel

                                              by Zacks Equity Research

                                              Sonoma's (SNOA) shares gain after the FDA approves its antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures.

                                                Zacks Equity Research

                                                Catalyst (CPRX) Up on New Drug Application for Firdapse

                                                by Zacks Equity Research

                                                Catalyst (CPRX) new drug application for its lead pipeline candidate keeps it on a growth trajectory.

                                                  Zacks Equity Research

                                                  Bio-Path Leukemia Combo Study Shows Positive Early Data

                                                  by Zacks Equity Research

                                                  Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.